Eton Pharmaceuticals acquired Galzin, the only FDA-approved zinc treatment for Wilson Disease, from Teva Pharmaceuticals for $7.0 million plus $0.2 million for inventory, and will pay a 10% royalty on U.S. net sales for ten years. Eton plans to comme...